Key Inclusion Criteria

Patients were eligible to be included in the trials only if they met all of the following criteria:

Key Exclusion Criteria

Patients were excluded from the trials if they had any of the following criteria:

• Male or female patients aged 18 years or older
• Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline
• At least 10% BSA of psoriasis at screening and baseline
• sPGA score ≥3 and PASI score ≥12 at screening and baseline
• Candidate for phototherapy and/or systemic therapy
• If male, must agree to use a reliable method of birth control or remain abstinent during the study
• If female, must agree to use reliable method of birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

• Pustular, erythrodermic, and/or guttate forms of psoriasis
• History of drug-induced psoriasis
• Prior use of etanercept
• Clinically significant flare of psoriasis during the 12 weeks prior to baseline
• Concurrent or recent (<5 half-lives prior to baseline) use of any biologic agent
• Received nonbiologic systemic psoriasis therapy or phototherapy (including PUVA and UVB) within 4 weeks prior to baseline or had topical psoriasis treatment within the previous 2 weeks prior to baseline
• Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to baseline and during the study
• Participated in any study with IL-17 antagonists, including ixekizumab
• Serious disorder or illness other than plaque psoriasis that would pose an unacceptable risk to the patient or interfere with the interpretation of data
• Serious infection within the last 12 weeks prior to baseline
• Evidence or suspicion of active or latent TB
• Breastfeeding or nursing (lactating) women